Vanguard Group’s Five Prime Therapeutics, Inc. FPRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q2 | – | Sell |
-2,169,678
| Closed | -$81.7M | – | 4490 |
|
|
2021
Q1 | $81.7M | Buy |
2,169,678
+98,951
| +5% | +$2.47M | ﹤0.01% | 2062 |
|
|
2020
Q4 | $35.2M | Buy |
2,070,727
+544,077
| +36% | +$6.82M | ﹤0.01% | 2373 |
|
|
2020
Q3 | $7.17M | Sell |
1,526,650
-15,036
| -1% | -$76.4K | ﹤0.01% | 2967 |
|
|
2020
Q2 | $9.4M | Sell |
1,541,686
-61,544
| -4% | -$254K | ﹤0.01% | 2806 |
|
|
2020
Q1 | $3.64M | Buy |
1,603,230
+7,771
| +0.5% | +$33K | ﹤0.01% | 3109 |
|
|
2019
Q4 | $7.32M | Sell |
1,595,459
-26,107
| -2% | -$103K | ﹤0.01% | 3004 |
|
|
2019
Q3 | $6.28M | Buy |
1,621,566
+51,745
| +3% | +$284K | ﹤0.01% | 3048 |
|
|
2019
Q2 | $9.47M | Sell |
1,569,821
-428,588
| -21% | -$4.1M | ﹤0.01% | 2892 |
|
|
2019
Q1 | $26.8M | Buy |
1,998,409
+650,399
| +48% | +$7.42M | ﹤0.01% | 2373 |
|
|
2018
Q4 | $12.5M | Sell |
1,348,010
-903,768
| -40% | -$10.8M | ﹤0.01% | 2659 |
|
|
2018
Q3 | $31.3M | Buy |
2,251,778
+66,485
| +3% | +$989K | ﹤0.01% | 2368 |
|
|
2018
Q2 | $34.5M | Buy |
2,185,293
+69,642
| +3% | +$1.22M | ﹤0.01% | 2319 |
|
|
2018
Q1 | $36.3M | Buy |
2,115,651
+306,197
| +17% | +$5.97M | ﹤0.01% | 2229 |
|
|
2017
Q4 | $39.7M | Buy |
1,809,454
+66,750
| +4% | +$2.15M | ﹤0.01% | 2178 |
|
|
2017
Q3 | $71.3M | Buy |
1,742,704
+88,767
| +5% | +$2.79M | ﹤0.01% | 1881 |
|
|
2017
Q2 | $49.8M | Sell |
1,653,937
-2,048
| -0.1% | -$63.9K | ﹤0.01% | 2020 |
|
|
2017
Q1 | $59.9M | Sell |
1,655,985
-526,860
| -24% | -$23.2M | ﹤0.01% | 1919 |
|
|
2016
Q4 | $109M | Buy |
2,182,845
+460,018
| +27% | +$24.2M | 0.01% | 1569 |
|
|
2016
Q3 | $90.4M | Buy |
1,722,827
+250,551
| +17% | +$12M | 0.01% | 1624 |
|
|
2016
Q2 | $60.9M | Buy |
1,472,276
+446,311
| +44% | +$19.4M | ﹤0.01% | 1809 |
|
|
2016
Q1 | $41.7M | Buy |
1,025,965
+200,373
| +24% | +$6.89M | ﹤0.01% | 1951 |
|
|
2015
Q4 | $34.3M | Buy |
825,592
+177,907
| +27% | +$5.96M | ﹤0.01% | 2062 |
|
|
2015
Q3 | $9.97M | Buy |
647,685
+73,880
| +13% | +$1.59M | ﹤0.01% | 2606 |
|
|
2015
Q2 | $14.3M | Buy |
573,805
+44,088
| +8% | +$982K | ﹤0.01% | 2501 |
|
|
2015
Q1 | $12.1M | Buy |
529,717
+218,238
| +70% | +$5.51M | ﹤0.01% | 2557 |
|
|
2014
Q4 | $8.41M | Buy |
311,479
+5,572
| +2% | +$95.9K | ﹤0.01% | 2622 |
|
|
2014
Q3 | $3.59M | Buy |
305,907
+57,930
| +23% | +$731K | ﹤0.01% | 3009 |
|
|
2014
Q2 | $3.86M | Buy |
247,977
+16,326
| +7% | +$234K | ﹤0.01% | 2980 |
|
|
2014
Q1 | $4.55M | Buy |
231,651
+192,053
| +485% | +$3.26M | ﹤0.01% | 2875 |
|
|
2013
Q4 | $665K | Buy |
+39,598
| New | +$492K | ﹤0.01% | 3523 |
|
Vanguard Group's FPRX Position: Q2 2021 in Review
Vanguard Group sold out of Five Prime Therapeutics, Inc. (FPRX) in Q2 2021, closing a stake of 2,169,678 shares — an estimated $81.7M sold.
Vanguard Group first reported a position in FPRX in Q4 2013 and held it in 30 quarters. The position peaked at $109M in Q4 2016. 0 funds tracked by Wall St. Rank hold FPRX as of Q2 2021.
- Vanguard Group reported no remaining Five Prime Therapeutics, Inc. position as of Q2 2021 after selling out during the quarter.
- Vanguard Group sold 2,169,678 Five Prime Therapeutics, Inc. shares in Q2 2021, an estimated $81.7M.
- Vanguard Group first reported a position in Five Prime Therapeutics, Inc. in Q4 2013 and held it in 30 quarters.
- Vanguard Group's Five Prime Therapeutics, Inc. position peaked at $109M in Q4 2016.
- 0 funds tracked by Wall St. Rank held Five Prime Therapeutics, Inc. as of Q2 2021.
Based on Vanguard Group's 13F filing for Q2 2021, filed 13 Aug 2021.